Clinical trials: Vinorelbine
Lung Cancer, Non Small Cell Lung Carcinoma
Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy
The trial investigates the feasibility and efficacy of targeting Non-Small Cell Lung Cancer (NSCLC) "driven" by epigenetic changes.
- Conditions
- Lung Cancer, Non Small Cell Lung Carcinoma, Hypermethylation
- Trial name
- NCT01209520
- Testing
- Cisplatin, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Miami
Neoplasms, Breast
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
This is a Phase II, randomized, open-label, multi-center study evaluating the efficacy and safety of lapatinib in combination with chemotherapy versus trastuzumab in combination with chemotherapy in women with HER2-positive and…
- Trial name
- NCT01137994
- Testing
- Lapatinib, Trastuzumab, Docetaxel
- Sponsor
- GlaxoSmithKline
Breast Cancer
Vinorelbine Plus Fluorouracil in Treating Women With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003730
- Testing
- fluorouracil, vinorelbine tartrate
- Where
- 17 sites in Belgium, France and 2 more
- Volunteers
- 80 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Metastatic Breast Cancer (MBC)
Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer
This multicenter, randomized, open, parallel positive control study compares the clinical efficacy and safety of paclitaxel polymeric micelles for injection with TPC in HER2- MBC subjects who have failed ≥2 to≤4 previous…
- Trial name
- NCT06143553
- Testing
- Paclitaxel Polymeric Micelles for Injection, Eribulin Mesilate injection, Capecitabine Tablets
- Where
- 3 sites in China
- Volunteers
- 168 people
- Sponsor
- Shanghai Yizhong Pharmaceutical Co., Ltd.
HER-2 Positive Breast Cancer
A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases
Purpose: This study is a single-arm, open-label phase II clinical trial testing the hypothesis that daily everolimus plus weekly vinorelbine and trastuzumab will be effective, safe, and tolerable among patients with human…
- Trial name
- NCT01305941
- Testing
- Everolimus, Vinorelbine, Trastuzumab
- Where
- 4 sites in United States
- Volunteers
- 32 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Carcinoma, Non-Small-Cell Lung
The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer
The standard treatment for non-small cell lung cancer, stage IV or IIIB malignant pleural effusion is chemotherapy. The decision to use a regimen is currently determined by toxicity or by physician's preference.
- Trial name
- NCT00215930
- Testing
- Vinorelbine, Docetaxel, Gemcitabine
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Non-small Cell Lung Cancer
Three Modalities of Treatment in Operable and Resectable Stage IIIA (T1-3, N2) Non-Small Cell Lung Cancer (NSCLC)
Stage IIIA non-small cell lung cancers comprising a mediastinal ganglionic invasion N2 account for 20 to 30% of the NSCLCs. They are almost always potentially resectable, but the results obtained by surgery alone or surgery…
- Trial name
- NCT00198367
- Testing
- Cisplatin-Gemzar, Cisplatin-Navelbine-Radiotherapy, Carboplatin-Taxol-Radiotherapy
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Hospices Civils de Lyon
Triple-Negative Breast Cancer
Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer
The study is being conducted to evaluate VEGFR BP102 with nab-paclitaxe or treatment of physician's choice (TPC) versus nab-paclitaxe or TPC in patients for basal-like immune suppressed (BLIS) subtype of triple-negative breast…
- Trial name
- BCTOP-T-M01 (NCT05806060)
- Testing
- VEGFR and TPC, TPC
- Where
- China
- Volunteers
- 134 people
- Sponsor
- Fudan University
Breast Cancer
Disitamab Vedotin in Combination with Metronomic Chemotherapy in Advanced HER2-expressing Breast Cancer.
This study aims to explore the efficacy of Disitamab vedotin in combination with metronomic chemotherapy in advanced breast cancer.
- Trial name
- NCT06857747
- Testing
- Capecitabine, Vinorelbine, Etoposide
- Volunteers
- 40 people
- Sponsor
- QIAO LI
Stage Ib Lung Carcinoma
Multicenter Randomized Controlled Trial Adjuvant Chemotherapy vs Observation in pStage Ib Lung Adenocarcinoma
Researchers developed the nomogram which evaluate the risk of recurrence after surgical resection, and found that the stage 1 NSCLC patients with more than 104 point of nomogram showed similar recurrence rate to the recurrence…
- Trial name
- NCT02281708
- Testing
- vinorelbine plus cisplatin
- Where
- South Korea
- Volunteers
- 1,012 people
- Sponsor
- Seoul National University Hospital
HER2-positive Locally Advanced or Metastatic Breast Cancer
A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer
The purpose of this study is to evaluate the efficacy and safety of pertuzumab, trastuzumab and chemotherapy as a pertuzumab retreatment compared to trastuzumab and chemotherapy in locally advanced or metastatic breast cancer…
- Trial name
- PRECIOUS (NCT02514681)
- Testing
- Trastuzumab, Pertuzumab, Docetaxel
- Where
- 3 sites in Japan
- Volunteers
- 226 people
- Sponsor
- Japan Breast Cancer Research Group
TNBC - Triple-Negative Breast Cancer
Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer
A real-world, multicenter, prospective study to evaluate the patient-reported outcome in Chinese patients who received sacituzumab govitecan or chemotherapy of the physician's choice for metastatic breast cancer progressing on…
- Trial name
- NCT07551050
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Fudan University
HER2-positive Breast Cancer, Metastatic Breast Cancer
Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab
Pyrotinib is an oral tyrosine kinase inhibitor targeting both HER-1 and HER-2 receptors. This study is a randomized, open-label, multi-center, parallel design study of the combination of pyrotinib, trastuzumab and chemotherapy…
- Trial name
- NCT05346861
- Testing
- Trastuzumab plus chemotherapy, Trastuzumab in combination with pyrotinib plus chemotherapy
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Fudan University
Pediatric Cancer
Study of a Propranolol (HEMANGIOL®) and Oral Metronomic Vinorelbine (NAVELBINE®) Combination for Children and Teenagers With Refractory/Relapsing Solid Tumors
Cancer remains the first cause of death due to disease in children and adolescents despite important progress and 70% of the survivors present sequelae.
- Trial name
- PROVIN (NCT02897986)
- Testing
- administration of a propranolol (HEMANGIOL®) and oral metronomic vinorelbine (NAVELBINE®) combination
- Where
- France
- Volunteers
- 54 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Lymphoma
Gemcitabine and Vinorelbine in Treating Young Patients With Recurrent or Refractory Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and vinorelbine, use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00070304
- Testing
- filgrastim, gemcitabine hydrochloride, vinorelbine tartrate
- Where
- 123 sites in United States, Australia and 3 more
- Volunteers
- 33 people
- Sponsor
- Children's Oncology Group
EGFR/ ALK-negative Advanced NSCLC
Metronomic Oral Vinorelbine Combination With Tislelizumab in EGFR/ALK-negative Advanced NSCLC
To evaluate the efficacy of metronomic chemotherapy combination with tislelizumab in EGFR/ALK-negative advanced NSCLC patients intolerant to first-line standard chemotherapy.
- Trial name
- NCT06260553
- Testing
- tislelizumab and metronomic oral vinorelbine
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fujian Cancer Hospital
Metastatic Non Small Cell Lung Cancer, Metastatic Breast Cancer
Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer
The purpose of this study is to determine the highest dose of Vinorelbine and Pazopanib that can be given together without causing severe side effects.
- Trial name
- NCT01060514
- Testing
- Pazopanib, Vinorelbine
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Northwestern University
Colorectal Cancer Metastatic
Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer
The purpose of the present study is to investigate the benefit of anti-cancer therapy administered on the basis of drug sensitivity testing. This concerns colorectal cancer patients who have previously received standard treatment.
- Trial name
- NCT03251612
- Testing
- Based on sensitivity analysis
- Where
- 4 sites in Denmark, Germany
- Volunteers
- 90 people
- Sponsor
- Vejle Hospital
Non-small Cell Lung Cancer
Effect of Endostar Combined With Chemotherapy and Radiotherapy on Blood Vessels and Microenvironment of Tumor for Non-small Cell Lung Cancer (NSCLC)
Primary objective: functional imaging and quantitative imaging detection of the effects of Endostar combined with chemotherapy and radiotherapy on Non-small Cell Lung Cancer (NSCLC).
- Trial name
- NCT01687439
- Testing
- Endostar, Vinorelbine, Cisplatin
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Fudan University
Metastatic Breast Cancer
Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer
The purpose of this study is to evaluate the efficacy and safety of SKB264 in patients with unresectable locally advanced, recurrent, or metastatic HR+/HER2- breast cancer.
- Trial name
- NCT06081959
- Testing
- SKB264, Eribulin, Capecitabine
- Where
- China
- Volunteers
- 376 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.